Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 33 peer-reviewed journal articles Updated
Oncology

What Happens When Imatinib Stops Working for GIST?

At a Glance

When imatinib stops working for GIST due to secondary mutations, oncologists follow an FDA-approved treatment path. The first step is often doubling the imatinib dose. If that fails, standard backup targeted therapies include sunitinib, regorafenib, and ripretinib based on your tumor profile.

In this answer

5 sections

01

Why Does Imatinib Stop Working?

02

Step 1: Imatinib Dose Escalation

03

The Sequential Treatment Algorithm

04

Focal Progression vs. Systemic Progression

05

The Role of Clinical Trials

Finding out that your gastrointestinal stromal tumor (GIST) is growing while taking imatinib (Gleevec) can be a scary and overwhelming moment. However, it is very common for GIST tumors to eventually find a way to outsmart the first drug, and medical oncology has a clear, established plan for when this happens. There is an FDA-approved step-by-step treatment algorithm designed specifically to target the new mutations that make the tumor resistant to imatinib [1][2].

Why Does Imatinib Stop Working?

Imatinib works by blocking specific signals—usually from the KIT or PDGFRA proteins—that tell GIST cells to grow. Over time, the tumor cells can mutate further to survive. These new genetic changes are called secondary mutations [2][3].

Because of these new mutations in the tumor’s DNA, the physical shape of the targeted protein changes. Imatinib is like a key meant for a specific lock; when the lock changes its shape (mutates), the key no longer fits [4][5][6]. This is known as acquired resistance.

When a scan shows that your tumor might be growing again, your care team may recommend new testing to see exactly how the “lock” has changed. They can do this via a repeat tissue biopsy or a liquid biopsy (a non-invasive blood test that looks for pieces of tumor DNA circulating in your bloodstream) [7][8]. Identifying your specific new mutations helps your doctor choose the most effective next step.

A Note on the PDGFRA D842V Mutation:
If your initial testing showed you have a mutation called PDGFRA D842V, your treatment path is different. These tumors are naturally resistant to imatinib and are often treated with a drug called avapritinib (Ayvakit) instead of the standard sequence listed below [9][10].

Step 1: Imatinib Dose Escalation

Before switching to a completely new drug, your doctor’s first step might simply be to increase your dose of imatinib [11][12]. Often, increasing the dose from 400 mg to 800 mg daily can overcome the initial resistance and control the tumor for a longer period [13]. This strategy is especially common for patients whose tumors originally had a specific mutation called KIT exon 9 [14].

  • Managing Side Effects: It is completely normal to worry that doubling the dose means your side effects will be twice as bad. While a higher dose can increase side effects like swelling (edema) and fatigue, your care team will help manage this [15][16]. Often, doctors prescribe the 800 mg as a “split dose” (400 mg twice a day) to make it easier for your body to tolerate, or they will adjust your supportive medications [13].

The Sequential Treatment Algorithm

When a higher dose of imatinib is no longer effective, or if the side effects become unmanageable, doctors move to the next backup drugs. These are also targeted therapies known as tyrosine kinase inhibitors (TKIs), but they are built to attack a wider variety of mutated “locks.”

Second-Line Therapy: Sunitinib

If imatinib stops working, the standard second-line treatment is sunitinib (Sutent) [1][2]. Sunitinib is a targeted therapy designed to block multiple signals that encourage tumor growth, including the signals that help the tumor build its own blood supply [17].

  • Side Effects to Watch: Sunitinib can cause different side effects than imatinib, including high blood pressure, fatigue, and hand-foot skin reaction (HFSR), which causes painful redness, swelling, or blistering on the palms and soles [18]. To manage HFSR, care teams often recommend wearing comfortable shoes to avoid friction and applying thick urea-based creams daily [19][20]. Your doctor can also briefly pause the medication or lower the dose if symptoms become severe [21].

Third-Line Therapy: Regorafenib

If the tumor eventually develops resistance to sunitinib, the approved third-line option is regorafenib (Stivarga) [2][1]. Regorafenib is a multi-kinase inhibitor, meaning it blocks a very broad range of cellular pathways. It retains strong activity against many of the specific secondary KIT mutations that cause resistance to both imatinib and sunitinib [22][3].

  • Side Effects to Watch: Like sunitinib, regorafenib can cause hand-foot syndrome, fatigue, diarrhea, and high blood pressure. Because these side effects can heavily impact your quality of life, your doctor will monitor you closely and may adjust your dose or schedule to help you tolerate the medication better [23][24][25].

Fourth-Line Therapy: Ripretinib

For GIST that has progressed after imatinib, sunitinib, and regorafenib, the FDA-approved fourth-line therapy is ripretinib (Qinlock) [26][27]. Ripretinib is a unique “switch-control” inhibitor [28][29]. Instead of just trying to fit into the altered lock, it physically forces the targeted protein into an “off” position. This allows it to broadly target a wide spectrum of primary and drug-resistant mutations [28][30].

  • Side Effects to Watch: Ripretinib is generally well-tolerated and is associated with fewer severe side effects than sunitinib [18]. However, it can cause hair thinning or loss (alopecia), fatigue, nausea, and mild hand-foot syndrome [18][31].

Focal Progression vs. Systemic Progression

Sometimes resistance is limited to just one or two spots that are growing, while the rest of the tumors are stable or shrinking. This is called focal progression. This scenario offers a unique option: instead of switching to a completely new drug, your doctor might recommend surgically removing, radiating, or freezing the single growing spot while you continue taking your current targeted therapy [2][32][33].

If tumors are growing in multiple locations at once, this is known as systemic progression. This usually indicates the current drug is no longer working throughout your body, meaning it is time to move to the next drug in the sequence.

The Role of Clinical Trials

Because GIST tumors are constantly trying to find ways around targeted therapies, clinical trials are a critical and standard part of the treatment landscape. Trials offer early access to newer, more advanced drugs designed to overcome specific resistance mutations. You can ask your doctor about clinical trials at any stage of your treatment journey—not just after you have tried all the standard options.

Common questions in this guide

Why does imatinib stop working for GIST?
Imatinib stops working when the GIST tumor cells develop new genetic changes, called secondary mutations. These mutations alter the physical shape of the proteins the drug targets, meaning the medication can no longer effectively block the signals that tell the tumor to grow.
Do I need to switch to a new drug immediately if my GIST starts growing on imatinib?
Not necessarily. Before switching to a completely new medication, your oncologist might recommend simply increasing your daily imatinib dose to 800 mg. This dose escalation can often overcome initial resistance and control the tumor for a longer period.
What happens if only one of my GIST tumors is growing?
If your tumor is only growing in one or two isolated spots—a situation called focal progression—your doctor might recommend surgically removing or radiating those specific spots. You may be able to continue taking your current medication rather than switching to a new drug.
What is the standard second-line treatment for GIST?
If a higher dose of imatinib is no longer effective, the standard second-line treatment is sunitinib (Sutent). This targeted therapy blocks a wider variety of mutated signals and helps stop the tumor from building its own blood supply.
Should I get another biopsy when my GIST progresses?
Your care team may recommend a repeat tissue biopsy or a non-invasive liquid biopsy (blood test) when your tumor starts growing again. This testing identifies the specific new mutations driving the resistance, which helps your doctor choose the most effective next therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor's progression focal (limited to one or two spots) or systemic, and does that mean I need a new drug or just a local treatment like surgery?
  2. 2.Should we order a liquid biopsy or repeat tissue biopsy now to check for specific new resistance mutations?
  3. 3.Am I a candidate for increasing my imatinib dose to 800 mg before switching to a completely new drug?
  4. 4.What specific side effects should I expect from this next treatment, and what can I do right now to prevent them (like using specialized creams for my hands and feet)?
  5. 5.Are there any clinical trials that might be a better fit for my specific tumor mutations right now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does GIST Treatment Cause Hair Loss? (Targeted Therapy)Do I Need to See a Sarcoma Specialist for GIST?What Happens When a GIST Tumor Ruptures? Risk & TreatmentIs GIST the Same as Stomach Cancer? Key DifferencesWhat Are the Long-Term Side Effects of Imatinib for GIST?Why Shrink a GIST Tumor Before Surgery with Imatinib?What is a High Mitotic Rate in GIST Pathology?What Is Wild-Type GIST and How Is It Treated?Where Does GIST Typically Spread or Recur?Why Is Small Intestine GIST Higher Risk Than Stomach GIST?

References

References (33)
  1. 1

    GEIS guidelines for gastrointestinal sarcomas (GIST).

    Poveda A, García Del Muro X, López-Guerrero JA, et al.

    Cancer treatment reviews 2017; (55()):107-119 doi:10.1016/j.ctrv.2016.11.011.

    PMID: 28351781
  2. 2

    An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.

    Schvartsman G, Wagner MJ, Zobniw CM, et al.

    Current oncology reports 2016; (18(8)):49 doi:10.1007/s11912-016-0536-7.

    PMID: 27319943
  3. 3

    Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor.

    Serrano C, Fletcher JA

    Oncotarget 2019; (10(59)):6286-6287 doi:10.18632/oncotarget.27277.

    PMID: 31695836
  4. 4

    CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?

    Antonescu CR, DeMatteo RP

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015; (21(15)):3363-5 doi:10.1158/1078-0432.CCR-14-3120.

    PMID: 26240289
  5. 5

    Selection between sunitinib and ripretinib using mutation analysis for gastrointestinal stromal tumor patients progressing on imatinib.

    Joensuu H

    Translational gastroenterology and hepatology 2024; (9()):52 doi:10.21037/tgh-24-32.

    PMID: 39503033
  6. 6

    The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor.

    Zhang JQ, Bosbach B, Loo JK, et al.

    Oncogene 2020; (39(49)):7153-7165 doi:10.1038/s41388-020-01489-4.

    PMID: 33024275
  7. 7

    Genomic profiling in GIST: Implications in clinical outcome and future challenges.

    Calderillo-Ruíz G, Pérez-Yepez EA, García-Gámez MA, et al.

    Neoplasia (New York, N.Y.) 2024; (48()):100959 doi:10.1016/j.neo.2023.100959.

    PMID: 38183711
  8. 8

    Clinical Use of Liquid-Based Comprehensive Genomic Profiling in Gastrointestinal Stromal Tumors.

    Mechahougui H, Hildebrand L, Haberberger J, et al.

    Laboratory investigation; a journal of technical methods and pathology 2025; (105(5)):104116 doi:10.1016/j.labinv.2025.104116.

    PMID: 39984125
  9. 9

    Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.

    Heinrich MC, Jones RL, von Mehren M, et al.

    The Lancet. Oncology 2020; (21(7)):935-946 doi:10.1016/S1470-2045(20)30269-2.

    PMID: 32615108
  10. 10

    miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.

    Huang WK, Akçakaya P, Gangaev A, et al.

    Experimental cell research 2018; (371(1)):287-296 doi:10.1016/j.yexcr.2018.08.028.

    PMID: 30149002
  11. 11

    Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.

    Mohammadi M, Jansen-Werkhoven TM, Ijzerman NS, et al.

    Targeted oncology 2022; (17(6)):627-634 doi:10.1007/s11523-022-00926-6.

    PMID: 36374447
  12. 12

    Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study.

    Hsu JT, Le PH, Kuo CF, et al.

    Oncotarget 2017; (8(41)):71128-71137 doi:10.18632/oncotarget.16795.

    PMID: 29050348
  13. 13

    Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses.

    Cho H, Ryu MH, Lee Y, et al.

    The oncologist 2019; (24(12)):e1443-e1449 doi:10.1634/theoncologist.2019-0009.

    PMID: 31315961
  14. 14

    Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.

    Vincenzi B, Napolitano A, Fiocco M, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2022; (28(8)):1672-1679 doi:10.1158/1078-0432.CCR-21-1665.

    PMID: 34615721
  15. 15

    A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

    Ben Ami E, Demetri GD

    Expert opinion on drug safety 2016; (15(4)):571-8 doi:10.1517/14740338.2016.1152258.

    PMID: 26865352
  16. 16

    The correlation of sarcopenia and adverse events of imatinib therapy postoperatively in gastrointestinal stromal tumor through computed tomography quantitative body composition.

    Shao X, Wu H, Huang C, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2024; (28(4)):375-380 doi:10.1016/j.gassur.2024.01.025.

    PMID: 38583886
  17. 17

    Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.

    Wagner AJ, Severson PL, Shields AF, et al.

    JAMA oncology 2021; (7(9)):1343-1350 doi:10.1001/jamaoncol.2021.2086.

    PMID: 34236401
  18. 18

    Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

    Bauer S, Jones RL, Blay JY, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(34)):3918-3928 doi:10.1200/JCO.22.00294.

    PMID: 35947817
  19. 19

    Management of Regorafenib-Induced Hand-Foot Skin Reaction with Topical Chinese Medicine and Urea Ointment: A Case Report and Literature Review.

    Liu ZN, Shen YL, Dong HJ, et al.

    OncoTargets and therapy 2025; (18()):509-519 doi:10.2147/OTT.S510766.

    PMID: 40225901
  20. 20

    Relationship between hand-foot skin reaction and external force on patients with hepatocellular carcinoma: A cohort study.

    Tahara Y, Amemiya A, Kase R, et al.

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2024; (70()):102576 doi:10.1016/j.ejon.2024.102576.

    PMID: 38642523
  21. 21

    Donafenib intolerance in hepatocellular carcinoma: severe hand-foot skin reaction and successful switch to lenvatinib - a case report and literature review.

    Chen Y, Fu L, Song P, et al.

    Frontiers in oncology 2025; (15()):1728098 doi:10.3389/fonc.2025.1728098.

    PMID: 41487570
  22. 22

    A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.

    Yeh CN, Chen MH, Chen YY, et al.

    Oncotarget 2017; (8(27)):44121-44130 doi:10.18632/oncotarget.17310.

    PMID: 28487491
  23. 23

    The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review.

    Khachatryan V, Muazzam A, Hamal C, et al.

    Cureus 2022; (14(9)):e28665 doi:10.7759/cureus.28665.

    PMID: 36199644
  24. 24

    Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.

    Kim JJ, Ryu MH, Yoo C, et al.

    The oncologist 2019; (24(11)):e1212-e1218 doi:10.1634/theoncologist.2019-0033.

    PMID: 31036770
  25. 25

    Association of adverse events and quality of life in patients with unresectable hepatocellular carcinoma.

    Agirrezabal I, Pollock RF, Carion PL, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2024; (33(12)):3377-3386 doi:10.1007/s11136-024-03779-w.

    PMID: 39412677
  26. 26

    Ripretinib for the treatment of advanced gastrointestinal stromal tumor.

    Zalcberg JR

    Therapeutic advances in gastroenterology 2021; (14()):17562848211008177 doi:10.1177/17562848211008177.

    PMID: 33948116
  27. 27

    Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib.

    Brackert S, Polson K

    Journal of the advanced practitioner in oncology 2023; (14(4)):317-328 doi:10.6004/jadpro.2023.14.4.6.

    PMID: 37313282
  28. 28

    Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Blay JY, Serrano C, Heinrich MC, et al.

    The Lancet. Oncology 2020; (21(7)):923-934 doi:10.1016/S1470-2045(20)30168-6.

    PMID: 32511981
  29. 29

    Ripretinib turns off the switch in GIST.

    Villanueva MT

    Nature reviews. Drug discovery 2019; (18(7)):499 doi:10.1038/d41573-019-00099-4.

    PMID: 31267077
  30. 30

    Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.

    Bauer S, Heinrich MC, George S, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(23)):6333-6342 doi:10.1158/1078-0432.CCR-21-1864.

    PMID: 34503977
  31. 31

    Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.

    Li J, Zhang J, Zhang Y, et al.

    European journal of cancer (Oxford, England : 1990) 2024; (196()):113439 doi:10.1016/j.ejca.2023.113439.

    PMID: 37980854
  32. 32

    Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.

    Zhang Y, Huang Z

    Frontiers in pharmacology 2023; (14()):1122885 doi:10.3389/fphar.2023.1122885.

    PMID: 37288114
  33. 33

    Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.

    Gao X, Xue A, Fang Y, et al.

    Scientific reports 2016; (6()):22840 doi:10.1038/srep22840.

    PMID: 26946961

This page explains GIST treatment sequencing and imatinib resistance for informational purposes only. Always consult your medical oncologist to determine the best treatment plan for your specific tumor profile.

Get notified when new evidence is published on Gastrointestinal stromal tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.